John R. Stuelpnagel - 18 Oct 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol
TXG
Transactions as of
18 Oct 2021
Net transactions value
-$753,343
Form type
4
Filing time
20 Oct 2021, 17:39:29 UTC
Previous filing
12 Oct 2021
Next filing
03 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Sale $662,260 -4,400 -1.2% $150.51 362,216 18 Oct 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale $45,424 -300 -0.08% $151.41 361,916 18 Oct 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale $45,659 -300 -0.08% $152.20 361,616 18 Oct 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $150.00 to $150.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $151.03 to $151.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $151.79 to $152.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.